Biswas Suvro, Mahmud Shafi, Mita Mohasana Akter, Afrose Shamima, Hasan Md Robiul, Sultana Shimu Mst Sharmin, Saleh Md Abu, Mostafa-Hedeab Gomaa, Alqarni Mohammed, Obaidullah Ahmad J, Batiha Gaber El-Saber
Department of Genetic Engineering and Biotechnology, University of Rajshahi, Rajshahi, Bangladesh.
Pharmacology Department and Health Research Unit-medical College, Jouf University, Jouf, Saudi Arabia.
Front Mol Biosci. 2022 Jan 27;8:791642. doi: 10.3389/fmolb.2021.791642. eCollection 2021.
The spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a pandemic due to the high transmission and mortality rate of this virus. The world health and economic sectors have been severely affected by this deadly virus, exacerbated by the lack of sufficient efficient vaccines. The design of effective drug candidates and their rapid development is necessary to combat this virus. In this study, we selected 23 antimicrobial peptides from the literature and predicted their structure using PEP-FOLD 3.5. In addition, we docked them to the SARS-CoV-2 spike protein receptor-binding domain (RBD) to study their capability to inhibit the RBD, which plays a significant role in virus binding, fusion and entry into the host cell. We used several docking programs including HDOCK, HPEPDOCK, ClusPro, and HawkDock to calculate the binding energy of the protein-peptide complexes. We identified four peptides with high binding free energy and docking scores. The docking results were further verified by molecular dynamics (MD) simulations to characterize the protein-peptide complexes in terms of their root-mean-square fluctuation (RMSF), root-mean-square deviation (RMSD), radius of gyration (Rg), solvent-accessible surface area (SASA), and hydrogen bond formation. Allergenicity and toxicity predictions suggested that the peptides we identified were non-allergenic and non-toxic. This study suggests that these four antimicrobial peptides could inhibit the RBD of SARS-CoV-2. Future and studies are necessary to confirm this.
严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的传播已成为一场大流行,因为这种病毒具有高传播率和死亡率。世界卫生和经济部门受到这种致命病毒的严重影响,而缺乏足够有效的疫苗使情况更加恶化。设计有效的候选药物并快速开发它们对于对抗这种病毒是必要的。在本研究中,我们从文献中选择了23种抗菌肽,并使用PEP-FOLD 3.5预测它们的结构。此外,我们将它们与SARS-CoV-2刺突蛋白受体结合域(RBD)进行对接,以研究它们抑制RBD的能力,RBD在病毒结合、融合和进入宿主细胞中起着重要作用。我们使用了包括HDOCK、HPEPDOCK、ClusPro和HawkDock在内的几种对接程序来计算蛋白质-肽复合物的结合能。我们鉴定出四种具有高结合自由能和对接分数的肽。对接结果通过分子动力学(MD)模拟进一步验证,以根据均方根波动(RMSF)、均方根偏差(RMSD)、回转半径(Rg)、溶剂可及表面积(SASA)和氢键形成来表征蛋白质-肽复合物。致敏性和毒性预测表明我们鉴定出的肽无致敏性且无毒。本研究表明这四种抗菌肽可以抑制SARS-CoV-2的RBD。未来需要进一步的研究来证实这一点。